In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Niagen Bioscience (NAGE – Research Report), with a price target of $11.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Ram Selvaraju has given his Buy rating due to a combination of factors that highlight Niagen Bioscience’s resilience and potential for growth. The company has effectively insulated its manufacturing process from global tariff impacts, as its key ingredient, Niagen, is produced domestically with minimal reliance on international materials. This strategic positioning ensures stable production costs and uninterrupted international operations, particularly in markets like Hong Kong that remain duty-free.
Furthermore, Niagen Bioscience is poised for potential expansion into the prescription pharmaceutical market, driven by promising clinical trials. The ongoing NO-PARK Phase 2/3 study is expected to yield results in the first half of 2025, potentially paving the way for a pharmaceutical-grade formulation of Niagen for Parkinson’s disease treatment. The positive outcomes from a recent Phase 1 trial reinforce the therapeutic promise of Niagen, supporting Selvaraju’s optimistic outlook and the reiteration of a 12-month price target of $11.
In another report released yesterday, Roth MKM also reiterated a Buy rating on the stock with a $8.00 price target.